You are here

  • Home
  • Archive
  • Volume 80, Issue 7
  • Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)

Article info

Article menu
Download PDFPDF
Letter
Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)

Authors

  1. Correspondence to Dr Daniel J Wallace, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048-0750, USA; danielwallac@gmail.com
View Full Text

Citation

Wallace DJ, Figueras F, Wegener WA, et al
Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)
Annals of the Rheumatic Diseases 2021;80:954-955.

Publication history

  • Received December 31, 2020
  • Revised January 25, 2021
  • Accepted February 10, 2021
  • First published February 22, 2021.
Online issue publication 
May 27, 2023

Article Versions

Copyright information

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.